Current status and future potential of advanced technologies in radiation oncology: Part 2. State of the science by anatomic site

ONCOLOGY

Volumn 23, Issue 4, 2009, Pages 380-385

  Vikram, Bhadrasain ^a   Coleman, C Norman ^a   Deye, James A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; CARMUSTINE; CETUXIMAB; CISPLATIN; TAMOXIFEN; TEMOZOLOMIDE;

ADVANCED CANCER; ANASTOMOSIS; ARTICLE; BLADDER DISEASE; BRAIN METASTASIS; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; CONVENTIONAL RADIATION THERAPY; CYSTITIS; DERMATITIS; DESQUAMATION; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DYSPHAGIA; EARLY CANCER; ERECTILE DYSFUNCTION; ERYTHEMA; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS HEMORRHAGE; ESOPHAGUS PERFORATION; ESOPHAGUS STRICTURE; ESOPHAGUS TOXICITY; FATIGUE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HEARING LOSS; HEMATURIA; HUMAN; INFECTION; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; INTESTINE OBSTRUCTION; LARYNGITIS; LEG EDEMA; LUNG DISEASE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MUCOSAL DISEASE; MUCOSAL TOXICITY; NASOPHARYNX CANCER; NAUSEA; NAUSEA AND VOMITING; PARTIAL MASTECTOMY; PERIPHERAL EDEMA; PHARYNGITIS; PHARYNX DISEASE; PHARYNX TOXICITY; PNEUMONIA; PROCTITIS; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE; RASH; RECTUM HEMORRHAGE; SIDE EFFECT; SKIN DISEASE; SKIN TOXICITY; SMALL INTESTINE OBSTRUCTION; STEREOTACTIC RADIATION THERAPY; STOMATITIS; URETHRA STRICTURE; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; URINE RETENTION; UROGENITAL TRACT DISEASE; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

BRAIN NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GLIOBLASTOMA; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION ONCOLOGY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; UNITED STATES;

EID: 65749089613     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Andrews DW, Scott UB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-1672, 2004.
2. Stupp R, Mason WP, van den Bent MJ, et al, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005.
3. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006.
4. Cooper JS, Pajak TF, Forastiere AA, et al, Radiation Therapy Oncology Group 9501/Intergroup: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004.
5. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003.
6. Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16:1310-1317, 1998.
7. Saunders M, Dische S, Barrett A, et al: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 52:137-148, 1999.
8. Sause W, Kolesar P, Taylor S IV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000.
9. Komaki R, Scott CB, Sause WT, et al: Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 39:537-544, 1997.
10. Turrisi AT 3rd, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999.
11. Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167-1174, 2002.
12. Fyles AW, McCready DR, Manchul LA, et al: Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351:963-970, 2004.
13. Ragaz J, Olivotto IA, Spinelli JJ, et al: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97:116-1126, 2005.
14. Regine WF, Winter KA, Abrams RA, et al: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 299:1019-1026, 2008.
15. Lawton CA, DeSilvio M, Lee WR, et al: Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05). Int J Radiat Oncol Biol Phys 67:39-47, 2007.
16. Thompson IM Jr, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296:2329-2335, 2006.
17. D'Amico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004.
18. D'Amico AV, Chen MH, Renshaw AA, et al: Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299:289-295, 2008.
19. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997.
20. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-108, 2002.
21. Ataman F, Zurlo A, Artignan X, et al: Late toxicity following conventional radiotherapy for prostate cancer: Analysis of the EORTC trial 22863. Eur J Cancer 40:1674-1681, 2004.
22. Morris M, Eifel PJ, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137-1143, 1999.
23. Creutzberg CL, van Putten WL, Koper PC, et al: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355:1404-1411, 2000.
24. Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004.
25. Ajani JA, Winter KA, Gunderson LL, et al: Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 299:1914-1921, 2008.
26. Souhami L, Seiferheld W, Brachman D, et al: Randomized comparison of stereo-tactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60:853-860, 2004.
27. Pow EH, Kwong DL, McMillan AS, et al: Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:981-991, 2006.
28. Kam MK, Leung SF, Zee B, et al: Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25:4873-4879, 2007.
29. Donovan E, Bleakley N, Denholm E, et al; Breast Technology Group: Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82:254-64, 2007.
30. Pignol JP, Olivotto I, Rakovitch E, et al: A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 26:2085-2092, 2008.
31. Shipley WU, Verhey LJ, Munzenrider JE, et al: Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32:3-12, 1995.
32. Gardner BG, Zietman AL, Shipley WU, et al: Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 167:123-126, 2002.